We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
-14.03%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$5.99B
AUM Growth
-$1.53B
Cap. Flow
+$245M
Cap. Flow %
4.09%
Top 10 Hldgs %
62.92%
Holding
100
New
11
Increased
14
Reduced
4
Closed
15

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$280M
2
SION
Sionna Therapeutics
SION
+$171M
3
IRON icon
Disc Medicine
IRON
+$87.7M
4
GERN icon
Geron
GERN
+$74M
5
ETNB
89bio
ETNB
+$50M

Top Sells

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$244M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$111M
3
AXSM icon
Axsome Therapeutics
AXSM
+$84.6M
4
VRNA
Verona Pharma
VRNA
+$82.1M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$58.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.82%
2 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SEPN
26
Septerna Inc
SEPN
$1.75B
$40.5M 0.68%
6,995,858
– –
TRML
27
DELISTED
Tourmaline Bio
TRML
$38.6M 0.64%
2,538,925
– –
CLYM
28
Climb Bio
CLYM
$764M
$38.3M 0.64%
31,419,267
– –
SRRK icon
29
Scholar Rock
SRRK
$6.17B
$36.5M 0.61%
1,136,453
+1,118,837
+6,351% +$43M
URGN icon
30
UroGen Pharma
URGN
$2.3B
$35.5M 0.59%
+3,206,271
New +$34.2M
ARTV
31
Artiva Biotherapeutics
ARTV
$565M
$29.6M 0.49%
9,853,302
– –
FULC icon
32
Fulcrum Therapeutics
FULC
$283M
$29.5M 0.49%
10,229,099
– –
VOR icon
33
Vor Biopharma
VOR
$1.23B
$28.4M 0.48%
1,982,302
– –
ATXS
34
DELISTED
Astria Therapeutics
ATXS
$27.3M 0.46%
5,105,213
– –
KURA icon
35
Kura Oncology
KURA
$830M
$26.4M 0.44%
4,004,610
-446,431
-10% -$3.48M
GPCR icon
36
Structure Therapeutics
GPCR
$3.67B
$26.3M 0.44%
1,517,418
– –
CDTX
37
DELISTED
Cidara Therapeutics
CDTX
$23.5M 0.39%
1,092,796
– –
JBIO
38
Jade Biosciences
JBIO
$1.36B
$23.1M 0.39%
262,631
– –
IDYA icon
39
IDEAYA Biosciences
IDYA
$3.5B
$22.1M 0.37%
1,347,252
– –
ITOS
40
DELISTED
iTeos Therapeutics
ITOS
$21.8M 0.36%
3,649,057
+1,556,798
+74% +$11.4M
TVTX icon
41
Travere Therapeutics
TVTX
$6.07B
$20.6M 0.34%
1,150,000
– –
NKTX icon
42
Nkarta
NKTX
$162M
$19.9M 0.33%
10,805,129
– –
GKOS icon
43
Glaukos
GKOS
$10.1B
$18.7M 0.31%
+190,256
New +$25.4M
MNPR icon
44
Monopar Therapeutics
MNPR
$826M
$18.6M 0.31%
511,207
– –
MTSR
45
DELISTED
Metsera Inc
MTSR
$18.4M 0.31%
+675,525
New +$19.1M
EYPT icon
46
EyePoint Inc
EYPT
$1.04B
$17.2M 0.29%
3,181,818
– –
TXG icon
47
10x Genomics
TXG
$5.74B
$17M 0.28%
1,944,247
-1,335,154
-41% -$16.8M
ACRV icon
48
Acrivon Therapeutics
ACRV
$71.1M
$16.9M 0.28%
8,340,508
– –
ELVN icon
49
Enliven Therapeutics
ELVN
$4.42B
$16.7M 0.28%
848,986
– –
ABOS icon
50
Acumen Pharmaceuticals
ABOS
$164M
$16.4M 0.27%
14,932,063
– –
1
2
3 4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $9.32B AUM 33.19% 1-Year Est. Return

RA Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, RA Capital Management held 100 positions worth $5.99B, down 20% from $7.51B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

RA Capital Management deployed $245M of net new capital in Q1 2025, opening 11 new positions and adding to 14 existing holdings. Its largest new stake was Sionna Therapeutics: 10,445,322 shares worth $109M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was 10x Genomics, an estimated $16.8M trimmed.

  • RA Capital Management's largest Q1 2025 buy was Sionna Therapeutics: 10,445,322 shares worth $109M.
  • RA Capital Management added most to Vaxcyte in Q1 2025, an estimated $280M increase.
  • RA Capital Management's biggest Q1 2025 reduction was 10x Genomics, cutting an estimated $16.8M.
  • RA Capital Management fully exited Legend Biotech in Q1 2025, selling an estimated $244M.
  • RA Capital Management's ten largest holdings make up 63% of its $5.99B portfolio in Q1 2025.
  • RA Capital Management opened 11 new positions and closed 15 in Q1 2025.
  • RA Capital Management's portfolio value fell 20% quarter-over-quarter to $5.99B.

Based on RA Capital Management's 13F filing for Q1 2025, filed 15 May 2025.